BIOAF (Bioasis Technologies) Debt-to-Equity : -0.82 (As of Nov. 2022)

View and export this data going back to 2009. Start your Free Trial

What is Bioasis Technologies Debt-to-Equity?

Bioasis Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2022 was $1.12 Mil. Bioasis Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2022 was $0.53 Mil. Bioasis Technologies's Total Stockholders Equity for the quarter that ended in Nov. 2022 was $-2.00 Mil. Bioasis Technologies's debt to equity for the quarter that ended in Nov. 2022 was -0.82.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bioasis Technologies's Debt-to-Equity or its related term are showing as below:

BIOAF's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Bioasis Technologies Debt-to-Equity Historical Data

The historical data trend for Bioasis Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Debt-to-Equity Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Debt-to-Equity

Get a 7-Day Free Trial

-0.40

0.28

-0.99

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Debt-to-Equity	Get a 7-Day Free Trial															-1.30	-0.99	-0.83	-1.18	-0.82

Competitive Comparison of Bioasis Technologies's Debt-to-Equity

For the Biotechnology subindustry, Bioasis Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioasis Technologies's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Bioasis Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bioasis Technologies's Debt to Equity Ratio for the fiscal year that ended in Feb. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.18	+	0.316)	/	-1.508
	=	-0.99

Bioasis Technologies's Debt to Equity Ratio for the quarter that ended in Nov. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.115	+	0.531)	/	-2.004
	=	-0.82

Bioasis Technologies (OTCPK:BIOAF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bioasis Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (OTCPK:BIOAF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.